Rakesh Rao1, Shamik Trivedi2, Zachary Vesoulis2, Steve M Liao2, Christopher D Smyser3, Amit M Mathur2. 1. Division of Newborn-Medicine, Department of Pediatrics, Washington University School of Medicine, St Louis, MO. Electronic address: Rao_R@kids.wustl.edu. 2. Division of Newborn-Medicine, Department of Pediatrics, Washington University School of Medicine, St Louis, MO. 3. Division of Pediatric Neurology, Departments of Neurology, Pediatrics, and Radiology, Washington University School of Medicine, St Louis, MO.
Abstract
OBJECTIVE: To evaluate the safety and short-term outcomes of preterm neonates born at 34-35 weeks gestation with hypoxic-ischemic encephalopathy (HIE) treated with therapeutic hypothermia. STUDY DESIGN: Medical records of preterm neonates born at 34-35 weeks gestational age with HIE treated with therapeutic hypothermia were retrospectively reviewed. Short-term safety outcomes and the presence, severity (mild, moderate, severe), and patterns of brain injury on magnetic resonance imaging were reviewed using a standard scoring system, and compared with a cohort of term neonates with HIE treated with therapeutic hypothermia. RESULTS: Thirty-one preterm and 32 term neonates were identified. Therapeutic hypothermia-associated complications were seen in 90% of preterm infants and 81.3% of term infants (P = .30). In the preterm infants, hyperglycemia (58.1% vs31.3%, P = .03) and rewarming before completion of therapeutic hypothermia (19.4% vs 0.0%, P = .009) were more likely compared with term infants. All deaths occurred in the preterm group (12.9% vs 0%, P = .04). Neuroimaging showed the presence of injury in 80.6% of preterm infants and 59.4% of term infants (P = .07), with no differences in injury severity. Injury to the white matter was more prevalent in preterm infants compared with term infants (66.7% vs 25.0%, P = .001). CONCLUSIONS: Therapeutic hypothermia in infants born at 34-35 weeks gestational age appears feasible. Risks of mortality and side effects warrant caution with use of therapeutic hypothermia in preterm infants.
OBJECTIVE: To evaluate the safety and short-term outcomes of preterm neonates born at 34-35 weeks gestation with hypoxic-ischemicencephalopathy (HIE) treated with therapeutic hypothermia. STUDY DESIGN: Medical records of preterm neonates born at 34-35 weeks gestational age with HIE treated with therapeutic hypothermia were retrospectively reviewed. Short-term safety outcomes and the presence, severity (mild, moderate, severe), and patterns of brain injury on magnetic resonance imaging were reviewed using a standard scoring system, and compared with a cohort of term neonates with HIE treated with therapeutic hypothermia. RESULTS: Thirty-one preterm and 32 term neonates were identified. Therapeutic hypothermia-associated complications were seen in 90% of preterm infants and 81.3% of term infants (P = .30). In the preterm infants, hyperglycemia (58.1% vs31.3%, P = .03) and rewarming before completion of therapeutic hypothermia (19.4% vs 0.0%, P = .009) were more likely compared with term infants. All deaths occurred in the preterm group (12.9% vs 0%, P = .04). Neuroimaging showed the presence of injury in 80.6% of preterm infants and 59.4% of term infants (P = .07), with no differences in injury severity. Injury to the white matter was more prevalent in preterm infants compared with term infants (66.7% vs 25.0%, P = .001). CONCLUSIONS: Therapeutic hypothermia in infants born at 34-35 weeks gestational age appears feasible. Risks of mortality and side effects warrant caution with use of therapeutic hypothermia in preterm infants.
Authors: Tammy N Tsuchida; Courtney J Wusthoff; Renée A Shellhaas; Nicholas S Abend; Cecil D Hahn; Joseph E Sullivan; Sylvie Nguyen; Steven Weinstein; Mark S Scher; James J Riviello; Robert R Clancy Journal: J Clin Neurophysiol Date: 2013-04 Impact factor: 2.177
Authors: Preethi Srinivasakumar; John Zempel; Shamik Trivedi; Michael Wallendorf; Rakesh Rao; Barbara Smith; Terrie Inder; Amit M Mathur Journal: Pediatrics Date: 2015-10-19 Impact factor: 7.124
Authors: Frances Cowan; Mary Rutherford; Floris Groenendaal; Paula Eken; Eugenio Mercuri; Graeme M Bydder; Linda C Meiners; Lilly M S Dubowitz; Linda S de Vries Journal: Lancet Date: 2003-03-01 Impact factor: 79.321
Authors: Seetha Shankaran; Abbot R Laptook; Richard A Ehrenkranz; Jon E Tyson; Scott A McDonald; Edward F Donovan; Avroy A Fanaroff; W Kenneth Poole; Linda L Wright; Rosemary D Higgins; Neil N Finer; Waldemar A Carlo; Shahnaz Duara; William Oh; C Michael Cotten; David K Stevenson; Barbara J Stoll; James A Lemons; Ronnie Guillet; Alan H Jobe Journal: N Engl J Med Date: 2005-10-13 Impact factor: 91.245
Authors: Jacqueline Salas; Nihaal Reddy; Emanuele Orru; Kathryn A Carson; Raul Chavez-Valdez; Vera Joanna Burton; Carl E Stafstrom; Frances J Northington; Thierry A G M Huisman Journal: J Neuroimaging Date: 2018-10-16 Impact factor: 2.486
Authors: Rakesh Rao; Shamik Trivedi; Amy Distler; Steve Liao; Zachary Vesoulis; Christopher Smyser; Amit M Mathur Journal: Am J Perinatol Date: 2019-01-04 Impact factor: 1.862
Authors: Felipe Kawa Odorcyk; R T Ribeiro; A C Roginski; L E Duran-Carabali; N S Couto-Pereira; C Dalmaz; M Wajner; C A Netto Journal: Mol Neurobiol Date: 2021-01-08 Impact factor: 5.590